RecruitingNot applicableNCT05974150

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Checked against the public recordLast updated Feb 23, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations7
SponsorCarevive Systems, Inc.
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Carevive Systems, Inc.
Interventions being studied
Other: Web based survey
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma. * Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. * All participants must be able to understand English. Exclusion Criteria: * Any patient who cannot understand written or spoken English. * Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. * Any patient on a treatment clinical trial. * Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Yale Cancer CenterNew Haven, Connecticut
  • Northshore University Health SystemEvanston, Illinois
  • Univeristy of North Carolina at Chapel HillChapel Hill, North Carolina
  • DukeDurham, North Carolina
  • Cleveland Clinic Mercy HospitalCanton, Ohio
  • University Hospitals Seidman Cancer CenterCleveland, Ohio
  • Tri-County Hematology & Oncology Associates, Inc.Massillon, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 23, 2026. Always confirm current availability with the study team.

View original record ↗